A new study showed that a single shot of liposomal-CBD can relieve pain in dogs suffering from osteoarthritis for six weeks.
The study was published in the Frontiers in Veterinary Science Journal and was sponsored by the multinational Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF). It has shown that a single subcutaneous injection of Liposomal-CBD can significantly reduce pain and improve the well-being of dogs affected by osteoarthritis for up to six weeks.
The term “liposomal” refers to a drug delivery system that uses liposomes, which are tiny, spherical vesicles made up of one or more phospholipid bilayers.
The study involved six dogs suffering from naturally-occurring osteoarthritis that were unresponsive to conventional medications. The dogs were treated with a single injection of 5 mg/kg liposomal-CBD, in addition to their routine medications.
The research team then observed the dogs for six weeks, measuring various parameters such as CBD plasma concentrations, blood work, collar activity data and evaluations of well-being and pain. The results were highly encouraging, with the dogs exhibiting a substantial drop in pain levels and an uptick in activity.
One of the key findings of the study was the prolonged detection of CBD in the plasma, with a peak concentration of 45.2 ng/ml (17.8-72.5 ng/ml). This suggests that the liposomal formulation of CBD has a long-lasting effect, potentially revolutionizing the way veterinarians manage osteoarthritis in dogs.
Another significant outcome was the increase in activity levels, objectively measured by the fifth and sixth weeks following the injection. This is particularly noteworthy as increased activity is often a reliable indicator of reduced pain and improved quality of life in animals.
Read more: Single dose of CBD reduces stress and anxiety in dogs: study
Read more: Martha Stewart and Canopy Growth release CBD dog treats — but are they safe?
Plasma cannabidiol (CBD) concentrations (ng/mL) in 6 dogs with osteoarthritis before and up to 42 days (6 weeks) following a single subcutaneous liposomal CBD injection at 5 mg/kg. Graph via Innocan.
While the study did note minor swelling at the injection site in five out of the six dogs, this side effect resolved within a few days without any treatment, indicating minimal safety concerns.
Innocan Pharma’s CEO, Iris Bincovich, said that the results, covered by one of the world’s leading publications, stand as a testament to the potential of its innovative formulations and drug delivery systems.
With the drug’s plasma concentrations detectable for six weeks and high exposure in terms of AUC (area under the concentration-time curve), the research suggests that this liposomal formulation could become a useful addition to pain management strategies for improving the quality of life in dogs with osteoarthritis.
Innocan Pharma is also exploring other applications of their liposomal CBD technology, including treatments for central nervous system disorders and COVID-19.
The study not only brings hope to pet owners and veterinarians but also adds a new dimension to the ongoing research in the field of CBD-based treatments. It marks a significant step forward in understanding the therapeutic potential of CBD, especially its liposomal formulation, in veterinary medicine.
